Laura B Harrington

Dr. Laura B Harrington


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2019 in Gerontology & Geriatrics Education
Verified
Journal Article
Closed access
BVBrenda Vrkljan
Brenda Vrkljan
AWAmanda Whalen
Amanda Whalen
TKTara Kajaks
Tara Kajaks
SNShaarujaa Nadarajah
Shaarujaa Nadarajah
P.J. WhiteP.J. White
P.J. White
PRParminder Raina
Parminder Raina
Intergenerational initiatives in post-secondary settings have demonstrated health and social benefits. However, there is a lack of detail with regard to the process by which such initiatives are conceptualized and the role of older and younger users in their development. Guided by the principles of an Age-Friendly University (AFU) alongside elements from a ‘Design Thinking’ approach, this project outlines the process undertaken to design a new intergenerational space to promote intergenerational connectivity. An online student survey (n = 504; 72.2% female) and focus groups were conducted with older adults (n = 22; 12 females; aged 70–95), which found similar themes across age groups with respect to: 1) past intergenerational experiences; 2) perceived benefits/challenges of accessing the space, and; 3) activity suggestions. Using these findings, alongside direct stakeholder input, Occupational Therapy students developed programming and design suggestions for the space in question aimed at strengthening interactions across age and ability. Results from this process indicate consulting with older and younger users can circumvent potential challenges and inform the design of campus-based initiatives that can promote intergenerational exchange.

30 April 2024 in Obesity Surgery
Verified
Journal Article
Closed access
PDF file
LHLaura B Harrington
Laura B Harrington
LBLuke Benz
Luke Benz
SHSebastien Haneuse
Sebastien Haneuse
EJEric Johnson
Eric Johnson
KCKaren J. Coleman
Karen J. Coleman
DADavid E. Arterburn
David E. Arterburn

7 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
SDSascha Dublin
Sascha Dublin
RWRod L Walker
Rod L Walker
JFJames S. Floyd
James S. Floyd
SSSusan M. Shortreed
Susan M. Shortreed
SFSharon Fuller
Sharon Fuller
BPBruce M. Psaty
Bruce M. Psaty
There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity. To examine the association between these medications and COVID-19 infection or hospitalization, we conducted a retrospective cohort study within a US integrated healthcare system. Among people aged ≥18 years enrolled in the health plan for at least 4 months as of 2/29/2020, current ACEI and ARB use was identified from pharmacy data, and the estimated daily dose was calculated and standardized across medications. COVID-19 infections were identified through 6/14/2020 from laboratory and hospitalization data. We used logistic regression to estimate adjusted odds ratios (ORs) and 95% confidence intervals. Among 322,044 individuals, 720 developed COVID-19 infection. Among people using ACEI/ARBs, 183/56,105 developed COVID-19 (3.3 per 1000 individuals) compared with 537/265,939 without ACEI/ARB use (2.0 per 1000), yielding an adjusted OR of 0.94 (95% CI 0.75-1.16). For use of < 1 defined daily dose vs. nonuse, the adjusted OR for infection was 0.89 (95% CI 0.62-1.26); for 1 to < 2 defined daily doses, 0.97 (95% CI 0.71-1.31); and for ≥2 defined daily doses, 0.94 (95% CI 0.72-1.23). The OR was similar for ACEIs and ARBs and in subgroups by age and sex. 29% of people with COVID-19 infection were hospitalized; the adjusted OR for hospitalization in relation to ACEI/ARB use was 0.92 (95% CI 0.54-1.57), and there was no association with dose. These findings support current recommendations that individuals on these medications continue their use.

6 June 2023 in BMJ Medicine
Verified
Journal Article
Open access
PDF file
VRVincent Lo Re
Vincent Lo Re
SDSarah K Dutcher
Sarah K Dutcher
JCJohn G Connolly
John G Connolly
SPSilvia Perez-Vilar
Silvia Perez-Vilar
DCDean M Carbonari
Dean M Carbonari
NCNoelle Cocoros
Noelle Cocoros
Objective To measure the 90 day risk of arterial thromboembolism and venous thromboembolism among patients diagnosed with covid-19 in the ambulatory (ie, outpatient, emergency department, or institutional) setting during periods before and during covid-19 vaccine availability and compare results to patients with ambulatory diagnosed influenza. Design Retrospective cohort study. Setting Four integrated health systems and two national health insurers in the US Food and Drug Administration's Sentinel System. Participants Patients with ambulatory diagnosed covid-19 when vaccines were unavailable in the US (period 1, 1 April-30 November 2020; n=272 065) and when vaccines were available in the US (period 2, 1 December 2020-31 May 2021; n=342 103), and patients with ambulatory diagnosed influenza (1 October 2018-30 April 2019; n=118 618). Main outcome measures Arterial thromboembolism (hospital diagnosis of acute myocardial infarction or ischemic stroke) and venous thromboembolism (hospital diagnosis of acute deep venous thrombosis or pulmonary embolism) within 90 days after ambulatory covid-19 or influenza diagnosis. We developed propensity scores to account for differences between the cohorts and used weighted Cox regression to estimate adjusted hazard ratios of outcomes with 95% confidence intervals for covid-19 during periods 1 and 2 versus influenza. Results 90 day absolute risk of arterial thromboembolism with covid-19 was 1.01% (95% confidence interval 0.97% to 1.05%) during period 1, 1.06% (1.03% to 1.10%) during period 2, and with influenza was 0.45% (0.41% to 0.49%). The risk of arterial thromboembolism was higher for patients with covid-19 during period 1 (adjusted hazard ratio 1.53 (95% confidence interval 1.38 to 1.69)) and period 2 (1.69 (1.53 to 1.86)) than for patients with influenza. 90 day absolute risk of venous thromboembolism with covid-19 was 0.73% (0.70% to 0.77%) during period 1, 0.88% (0.84 to 0.91%) during period 2, and with influenza was 0.18% (0.16% to 0.21%). Risk of venous thromboembolism was higher with covid-19 during period 1 (adjusted hazard ratio 2.86 (2.46 to 3.32)) and period 2 (3.56 (3.08 to 4.12)) than with influenza. Conclusions Patients diagnosed with covid-19 in the ambulatory setting had a higher 90 day risk of admission to hospital with arterial thromboembolism and venous thromboembolism both before and after covid-19 vaccine availability compared with patients with influenza.

16 March 2021 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
LHLaura B Harrington
Laura B Harrington
AEAlexa N. Ehlert
Alexa N. Ehlert
ETEvan L. Thacker
Evan L. Thacker
NJNancy S. Jenny
Nancy S. Jenny
OLOscar Lopez
Oscar Lopez
MJMajken K. Jensen
Majken K. Jensen

20 February 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
LHLaura B Harrington
Laura B Harrington
KCKara L. Cushing-Haugen
Kara L. Cushing-Haugen
SNSteve Nguyen
Steve Nguyen
JBJohn Bellettiere
John Bellettiere
MLMichael J. LaMonte
Michael J. LaMonte
ALAndrea Z. LaCroix
Andrea Z. LaCroix